Zobrazeno 1 - 10
of 303
pro vyhledávání: '"Winald R. Gerritsen"'
Autor:
Kalijn F. Bol, Gerty Schreibelt, Martine Bloemendal, Wouter W. van Willigen, Simone Hins-de Bree, Anna L. de Goede, Annemiek J. de Boer, Kevin J. H. Bos, Tjitske Duiveman-de Boer, Michel A. M. Olde Nordkamp, Tom G. M. van Oorschot, Carlijn J. Popelier, Jeanne M. Pots, Nicole M. Scharenborg, Mandy W. M. M. van de Rakt, Valeska de Ruiter, Wilmy S. van Meeteren, Michelle M. van Rossum, Sandra J. Croockewit, Bouke J. Koeneman, Jeroen H. A. Creemers, Inge M. N. Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A. van der Veldt, Dirk J. van Grünhagen, Johanna E. M. Werner, Johannes J. Bonenkamp, John B. A. G. Haanen, Marye J. Boers-Sonderen, Rutger H. T. Koornstra, Martijn F. Boomsma, Erik H. J. Aarntzen, Martin Gotthardt, James Nagarajah, Theo J. M. de Witte, Carl G. Figdor, Johannes H. W. de Wilt, Johannes Textor, Jan Willem B. de Groot, Winald R. Gerritsen, I. Jolanda M. de Vries
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were r
Externí odkaz:
https://doaj.org/article/245269452ff04a81b46a9a6846fb6516
Autor:
Sandra van Wilpe, Donjetë Simnica, Peter Slootbeek, Thomas van Ee, Samhita Pamidimarri Naga, Mark A. J. Gorris, Lieke L. van der Woude, Shabaz Sultan, Rutger H. T. Koornstra, Inge M. van Oort, Winald R. Gerritsen, Leonie I. Kroeze, Michiel Simons, Geert J. L. H. van Leenders, Mascha Binder, I. Jolanda M. de Vries, Niven Mehra
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Homologous recombination repair deficiency (HRD) is observed in 10% of patients with castrate-resistant prostate cancer (PCa). Preliminary data suggest that HRD-PCa might be more responsive to immune checkpoint inhibitors (ICIs). In this study, we co
Externí odkaz:
https://doaj.org/article/abdf79f8e7f4443f9c8ac5c4111ac941
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Willemijn A. van Gemert, Michel de Groot, Harm Westdorp, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Abstract Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-fr
Externí odkaz:
https://doaj.org/article/d0eae2f7bc184b94b9f6863ede0c30e8
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastati
Externí odkaz:
https://doaj.org/article/05ea3477df904c7e9eba15f0eafa2c79
Autor:
Sandra van Wilpe, Mark A. J. Gorris, Lieke L. van der Woude, Shabaz Sultan, Rutger H. T. Koornstra, Antoine G. van der Heijden, Winald R. Gerritsen, Michiel Simons, I. Jolanda M. de Vries, Niven Mehra
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
Checkpoint inhibitors targeting PD-(L)1 induce objective responses in 20% of patients with metastatic urothelial cancer (UC). CD8+ T cell infiltration has been proposed as a putative biomarker for response to checkpoint inhibitors. Nevertheless, data
Externí odkaz:
https://doaj.org/article/4b7c828cac8b4c238f41fdac1f8e8bc5
Autor:
Martine Bloemendal, Kalijn F. Bol, Steve Boudewijns, Mark A.J. Gorris, Johannes H.W. de Wilt, Sandra A.J. Croockewit, Michelle M. van Rossum, Anna L. de Goede, Katja Petry, Rutger H.T. Koornstra, Carl Figdor, Winald R. Gerritsen, Gerty Schreibelt, I. Jolanda M. de Vries
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
We evaluated the immunological responses of lymph-node involved (stage III) melanoma patients to adjuvant dendritic cell vaccination with subsets of naturally occurring dendritic cells (nDCs). Fifteen patients with completely resected stage III melan
Externí odkaz:
https://doaj.org/article/dfeb5f9d6c48480e92a7469ad71b0589
Autor:
Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Gerty Schreibelt, Mark A. J. Gorris, Niven Mehra, Michiel Simons, Anna L. de Goede, Michelle M. van Rossum, Alexandra J. Croockewit, Carl G. Figdor, J. Alfred Witjes, Erik H. J. G. Aarntzen, Roel D. M. Mus, Mareke Brüning, Katja Petry, Martin Gotthardt, Jelle O. Barentsz, I. Jolanda M. de Vries, Winald R. Gerritsen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Clinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-derived CD1c+ myeloi
Externí odkaz:
https://doaj.org/article/4dc02aee961d45088f68d31ad80e605a
Autor:
Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Niven Mehra, Simone M. Hins-de Bree, Carl G. Figdor, J. Alfred Witjes, Gerty Schreibelt, I. Jolanda M. de Vries, Winald R. Gerritsen, Petronella B. Ottevanger
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
BackgroundMaintaining health-related quality of life (HRQoL) is highly desirable during systemic therapies for patients with castration-resistant prostate cancer (CRPC). Patient-reported outcome measures (PROs) were studied in our phase IIa trial on
Externí odkaz:
https://doaj.org/article/1a4468dd63ae4da4bf9a44f25eee39a1
Autor:
Wouter W. van Willigen, Martine Bloemendal, Marye J. Boers-Sonderen, Jan Willem B. de Groot, Rutger H.T. Koornstra, Astrid A.M. van der Veldt, John B. A. G. Haanen, Steve Boudewijns, Gerty Schreibelt, Winald R. Gerritsen, I. Jolanda M. de Vries, Kalijn F. Bol
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Vaccination with autologous dendritic cells (DC) loaded ex vivo with melanoma-associated antigens is currently being tested as an adjuvant treatment modality for resected locoregional metastatic (stage III) melanoma. Based on its mechanism of action,
Externí odkaz:
https://doaj.org/article/883495aae3294bf5ba2d0568adb468a3
Autor:
Sandra van Wilpe, Victoria Wosika, Laura Ciarloni, Sahar Hosseinian Ehrensberger, Rachel Jeitziner, Paolo Angelino, Tjitske Duiveman-de Boer, Rutger H. T. Koornstra, I. Jolanda M. de Vries, Winald R. Gerritsen, Jack Schalken, Niven Mehra
Publikováno v:
Cancers, Vol 13, Iss 18, p 4660 (2021)
Although immune checkpoint inhibitors improve median overall survival in patients with metastatic urothelial cancer (mUC), only a minority of patients benefit from it. Early blood-based response biomarkers may provide a reliable way to assess respons
Externí odkaz:
https://doaj.org/article/29c1a1d3bffa42d3b16e17339e60937a